Hemophilia Federation of America: Assisting and Advocating for the Bleeding Disorders Community

Health News

Infusion Set Needles [Manufactured by Nipro for Exelint]: Recall

Print This Post Print This Post Posted on: January 26th, 2010 by sswindle | Leave a comment

Exel/Exelint Huber needles,
Exel/Exelint Huber Infusion Sets
Exel/Exelint “Securetouch+” Safety Huber Infusion Sets

Audience: Hospital Risk Managers, Surgical Service personnel

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint “Securetouch+” Safety Huber Infusion Sets, manufactured by Nipro …

Posted: 11/6/2009

Print This Post Print This Post Posted on: November 6th, 2009 by sswindle | Leave a comment

Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion (PDF – 68KB)

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Print This Post Print This Post Posted on: November 2nd, 2009 by sswindle | Leave a comment

26. October 2009 08:42

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB). Hemophilia is a rare and debilitating genetic …

Heparin: Change in Reference Standard

Print This Post Print This Post Posted on: October 1st, 2009 by sswindle | Leave a comment

FDA MedWatch

Heparin: Change in Reference Standard – The change will result in 10% reduction in the potency of the heparin marketed in the U.S.

Audience: Pharmacists, physicians, hospital risk managers and consumers

FDA notified healthcare professionals and patients of a change to heparin, effective October 1, 2009, which will include a new …

CDC: Effect of Antiretroviral Therapy on Risk of Sexual Transmission of HIV Infection and Superinfection

Print This Post Print This Post Posted on: September 9th, 2009 by khaugstad | Leave a comment

Effect of Antiretroviral Therapy on Risk of Sexual Transmission of HIV Infection and Superinfection

Keeping Blood Transfusions Safe: FDA’s Multi-layered Protections for Donated Blood

Print This Post Print This Post Posted on: September 3rd, 2009 by sswindle | Leave a comment

Vaccines, Blood & Biologics

Keeping the United States blood supply the world’s safest is the ultimate responsibility of the nation’s more than 3,000 blood establishments, which collect and process 14 million units of whole blood donated by volunteers each year. The Food and Drug Administration, however, has the vital role

Ablynx Initiates Phase II Clinical Trial for Alx-0081

Print This Post Print This Post Posted on: September 3rd, 2009 by sswindle | Leave a comment


Print
E-mail

01 Sep 2009

Ablynx announced the initiation of a Phase II study for its anti-thrombotic Nanobody …

September IS Pain Awareness Month

Print This Post Print This Post Posted on: August 26th, 2009 by sswindle | Leave a comment

Greetings:

September is Pain Awareness Month and the American Pain Foundation invites you to join us in sounding the alarm in communities across the country about the barriers to accessing appropriate and effective pain management and the desperate need for better pain care. This year’s campaign, Conquering

Ablynx Will Announce Half-Year Results For 2009 With Webcast

Print This Post Print This Post Posted on: August 25th, 2009 by sswindle | Leave a comment

Ablynx Will Announce Half-Year Results For 2009 With Webcast
PharmaLive.com (press release) – Newtown,PA,USA
ALX-0681, a subcutaneous formulation of the novel anti-thrombotic Nanobodies® that also selectively targets von Willebrand factor (vWF) has concluded Phase …

Media Briefing on 2009 H1N1 Flu

Print This Post Print This Post Posted on: August 21st, 2009 by RSS | Leave a comment

CDC will host a telephone-only briefing to provide an update on cases of 2009 H1N1 flu. The briefing will also include an update on NIH’s clinical trials of candidate 2009 H1N1 influenza vaccine.